Rini Dina Mustika, Xu Wenxi, Suzuki Takuya
Department of Food Technology, Faculty of Engineering, Universitas Pembangunan Nasional "Veteran" Jawa Timur, Surabaya 60294, Indonesia.
Key Laboratory of Functional Dairy, Co-Constructed by Ministry of Education and Beijing Municipality, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100193, China.
Prev Nutr Food Sci. 2024 Jun 30;29(2):93-105. doi: 10.3746/pnf.2024.29.2.93.
The intestinal epithelium plays an important role in maintaining the intestinal barrier and facilitating nutrient absorption. It also serves as a critical physical barrier against the infiltration of foreign substances from the intestinal lumen into the circulation. Intestinal barrier dysfunction has been implicated in the development of several diseases. Isomaltooligosaccharides (IMOs), which are a type of dietary fiber, possess multiple health benefits. However, there is limited information regarding their efficacy against gastrointestinal diseases. This review explores the therapeutic potential of IMOs in obesity, diabetes mellitus, inflammatory bowel disease (IBD), hyperlipidemia, and constipation. High-fat diet (HFD)-induced obesity models have shown that IMOs, administered alone or in combination with other compounds, exhibit potent antiobesity effects, making them promising agents in the treatment of obesity and its associated complications. Moreover, IMOs exhibit preventive effects against HFD-induced metabolic dysfunction by modulating gut microbiota and short-chain fatty acid levels, thereby ameliorating symptoms. Furthermore, IMOs can reduce IBD and alleviate hyperlipidemia, as indicated by the reduced histological colitis scores and improved lipid profiles observed in clinical trials and animal studies. This review highlights IMOs as a versatile intervention strategy that can improve gastrointestinal health by modulating gut microbiota, immune responses, and metabolic parameters, providing a multifaceted approach to address the complex nature of gastrointestinal disorders.
肠上皮在维持肠道屏障和促进营养吸收方面发挥着重要作用。它还作为一道关键的物理屏障，防止外来物质从肠腔渗入循环系统。肠道屏障功能障碍与多种疾病的发生有关。低聚异麦芽糖（IMOs）作为一种膳食纤维，具有多种健康益处。然而，关于其对胃肠道疾病疗效的信息有限。本综述探讨了IMOs在肥胖症、糖尿病、炎症性肠病（IBD）、高脂血症和便秘方面的治疗潜力。高脂饮食（HFD）诱导的肥胖模型表明，单独使用或与其他化合物联合使用的IMOs具有强大的抗肥胖作用，使其成为治疗肥胖症及其相关并发症的有前景的药物。此外，IMOs通过调节肠道微生物群和短链脂肪酸水平，对HFD诱导的代谢功能障碍具有预防作用，从而改善症状。此外，如临床试验和动物研究中观察到的组织学结肠炎评分降低和血脂谱改善所示，IMOs可以减轻IBD并缓解高脂血症。本综述强调IMOs是一种通用的干预策略，可通过调节肠道微生物群、免疫反应和代谢参数来改善胃肠道健康，为解决胃肠道疾病的复杂性提供了一种多方面的方法。
